Three Low-Price Biotechs That Could Pop (Or Drop) In 2016
Clinical-stage biotech stocks can trade wildly based on the latest news on drugs in trials and that's especially true of small-cap biotech companies researching cancer treatments.
Because cancer drugs are among those most likely to fail in studies, results from trials under way at Agenus(NASDAQ:AGEN), Array BioPharma(NASDAQ:ARRY), and Idera Pharmaceuticals(NASDAQ:IDRA) could move shares significantly higher or lower in the coming year, so let's learn more about these companies and the drugs that they're developing.
Hey, check out all the research scientist jobs. Post your resume today!
Because cancer drugs are among those most likely to fail in studies, results from trials under way at Agenus(NASDAQ:AGEN), Array BioPharma(NASDAQ:ARRY), and Idera Pharmaceuticals(NASDAQ:IDRA) could move shares significantly higher or lower in the coming year, so let's learn more about these companies and the drugs that they're developing.
Hey, check out all the research scientist jobs. Post your resume today!